Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Daiichi Sankyo
Express Scripts

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,417,175

« Back to Dashboard

Which drugs does patent 6,417,175 protect, and when does it expire?

Patent 6,417,175 protects TEFLARO and is included in one NDA. There has been one Paragraph IV challenge on Teflaro.

This patent has twenty patent family members in sixteen countries.

Summary for Patent: 6,417,175

Title: Phosphonocephem derivatives, process for the preparation of the same, and use thereof
Abstract:A novel cephem compound of the formula: ##STR1## wherein R.sup.1 is a phosphono group or a group convertible to a phosphono group; R.sup.2 is a hydrogen atom or a group having a linkage through a carbon atom; each of Q and X is a nitrogen atom or CH; Y is S, O or CH.sub.2 ; n is 0 or 1; one of R.sup.3 and R.sup.4 is a pyridinium group which may be substituted and the other is a hydrogen atom or hydrocarbon group which may be substituted, or R.sup.3 and R.sup.4 taken together may form a quaternalized nitrogen-containing heterocyclic ring which may be substituted, or its ester or its salt, which has a superior anti-bacterial activity, stability, absorbability, etc., a production thereof and a pharmaceutical composition containing it, is provided.
Inventor(s): Ishikawa; Tomoyasu (Otsu, JP), Hashiguchi; Shohei (Toyonaka, JP), Iizawa; Yuji (Muko, JP)
Assignee: Takeda Chemical Industries, Ltd. (Osaka, JP)
Application Number:09/555,949
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
CerexaTEFLAROceftaroline fosamilPOWDER;IV (INFUSION)200327-001Oct 29, 2010RXYesNo► Subscribe► Subscribe► SubscribeYYMETHODS FOR TREATING BACTERIAL INFECTIONS
CerexaTEFLAROceftaroline fosamilPOWDER;IV (INFUSION)200327-002Oct 29, 2010RXYesYes► Subscribe► Subscribe► SubscribeYYMETHODS FOR TREATING BACTERIAL INFECTIONS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,417,175

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan9-351499Dec 19, 1997
PCT Information
PCT FiledDecember 17, 1998PCT Application Number:PCT/JP98/05709
PCT Publication Date:July 01, 1999PCT Publication Number: WO99/32497

International Patent Family for Patent: 6,417,175

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Luxembourg92134► Subscribe
South Korea100384047► Subscribe
Japan2009114202► Subscribe
Japan2001048893► Subscribe
Japan3467418► Subscribe
JapanH11255772► Subscribe
Spain2325139► Subscribe
European Patent Office2080765► Subscribe
European Patent Office1043327► SubscribeCA 2013 00003Denmark► Subscribe
European Patent Office1043327► SubscribeC300568Netherlands► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Chinese Patent Office
Farmers Insurance
Daiichi Sankyo
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: